A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Biochemical Pharmacology

• Publication date

  2015-05-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bcp.2015.03.004PMID 25795251
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A novel orally active water-soluble inhibitor of human glutathione transferase exerts a potent and selective antitumor activity against human melanoma xenografts

  2015cited by this paper
• Synthesis and structure--activity relationship of new cytotoxic agents targeting human glutathione-S-transferases.

  2015cited by this paper
• Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib

  2014cited by this paper
• eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies

  2014cited by this paper
• The fine-tuning of TRAF2–GSTP1-1 interaction: effect of ligand binding and in situ detection of the complex

  2014cited by this paper
• Pathways and therapeutic targets in melanoma

  2014cited by this paper
• Glutathione S‐transferase P1‐1 as a target for mesothelioma treatment

  2013cited by this paper
• Challenging resistance mechanisms to therapies for metastatic melanoma.

  2013cited by this paper
• Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

  2013cited by this paper
• Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.

  2012cited by this paper
• Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine

  2012cited by this paper
• Targeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and -resistant human osteosarcoma cell lines.

  2012cited by this paper
• p53 Binding Prevents Phosphatase-mediated Inactivation of Diphosphorylated c-Jun N-terminal Kinase*

  2012cited by this paper
• Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.

  2012cited by this paper
• New insights into the mechanism of JNK1 inhibition by glutathione transferase P1-1.

  2012cited by this paper
• Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.

  2012cited by this paper
• RAS Interaction with PI3K: More Than Just Another Effector Pathway.

  2011cited by this paper
• Role of p53 Serine 46 in p53 Target Gene Regulation

  2011cited by this paper
• Targeting Glutathione-S Transferase Enzymes in Musculoskeletal Sarcomas: A Promising Therapeutic Strategy

  2011cited by this paper
• The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma.

  2011cited by this paper
• RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.

  2010cited by this paper
• Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death

  2010cited by this paper
• ERK and cell death: Mechanisms of ERK‐induced cell death – apoptosis, autophagy and senescence

  2010cited by this paper
• In vitro and in vivo efficacy of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human melanoma.

  2009cited by this paper
• All JNKs Can Kill, but Nuclear Localization Is Critical for Neuronal Death*

  2008cited by this paper
• Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity.

  2008cited by this paper
• Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

  2006cited by this paper
• Human glutathione S-transferase P1-1 interacts with TRAF2 and regulates TRAF2–ASK1 signals

  2006cited by this paper
• A Strong Glutathione S-Transferase Inhibitor Overcomes the P-glycoprotein-mediated Resistance in Tumor Cells

  2006cited by this paper
• 7-Nitro-2,1,3-benzoxadiazole Derivatives, a New Class of Suicide Inhibitors for Glutathione S-Transferases

  2005cited by this paper
• Essential role of p53 phosphorylation by p38 MAPK in apoptosis induction by the HIV-1 envelope

  2005cited by this paper
• Proapoptotic activity of new glutathione S-transferase inhibitors.

  2005cited by this paper
• Glutathione transferases.

  2005cited by this paper
• Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.

  2003cited by this paper
• BRAF and RAS mutations in human lung cancer and melanoma.

  2002cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Post-translational modifications and activation of p53 by genotoxic stresses.

  2001cited by this paper
• MEKK1 Binds Raf-1 and the ERK2 Cascade Components*

  2000cited by this paper
• GST function in drug and stress response.

  1999cited by this paper
• Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain.

  1999cited by this paper
• Regulation of JNK signaling by GSTp

  1999cited by this paper
• Phosphorylation of human p53 by p38 kinase coordinates N‐terminal phosphorylation and apoptosis in response to UV radiation

  1999cited by this paper
• ASK1 is essential for JNK/SAPK activation by TRAF2.

  1998cited by this paper

• Diclofenac Enhances the Response of BRAF Inhibitor to Melanoma Through ROS/p38/p53 Signaling

  2025cites this paper
• Cocaine-Induced Cardiac Alterations: Histological and Immunohistochemical Post-Mortem Analysis

  2025influential citation
• Discovery of Cdc20/Hsp90 Dual-Target Inhibitors with Potent Antitumor Activity for Therapy of Acquired Resistant Melanoma.

  2025cites this paper
• Survey on computer-aided automated melanoma detection

  2024cites this paper
• Glutathione S-transferase: A versatile and dynamic enzyme.

  2024cites this paper
• BS148 Reduces the Aggressiveness of Metastatic Melanoma via Sigma-2 Receptor Targeting

  2023cites this paper
• Overexpression of Glutathione S-Transferases in Human Diseases: Drug Targets and Therapeutic Implications

  2023cites this paper
• Identification of Dihydrolipoamide Dehydrogenase as Potential Target of Vemurafenib-Resistant Melanoma Cells

  2022cites this paper
• Implications of glutathione-S transferase P1 in MAPK signaling as a CRAF chaperone: In memory of Dr. Irving Listowsky

  2022cites this paper
• NBDHEX re‐sensitizes adriamycin‐resistant breast cancer by inhibiting glutathione S‐transferase pi

  2022cites this paper
• Anti-influenza A virus activity and structure–activity relationship of a series of nitrobenzoxadiazole derivatives

  2021cites this paper
• Characterization of Water-Soluble Esters of Nitrobenzoxadiazole-Based GSTP1-1 Inhibitors for Cancer Treatment.

  2020cites this paper
• Juglone potentiates BRAF inhibitor‑induced apoptosis in melanoma through reactive oxygen species and the p38‑p53 pathway.

  2020cites this paper
• Juglone potentiates BRAF inhibitor‑induced apoptosis in melanoma through reactive oxygen species and the p38‑p53 pathway

  2020cites this paper
• Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review

  2020cites this paper
• Mathematical Methods for Modelling Biological Heterogeneity

  2019cites this paper
• R

  2019cites this paper
• Glutathione transferase P silencing promotes neuronal differentiation of retinal R28 cells

  2019cites this paper
• Concentration-Dependent Dual Effects of Ciprofloxacin on SB-590885-Resistant BRAFV600E A375 Melanoma Cells.

  2019cites this paper
• Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies

  2019cites this paper
• Synthesis and characterisation of a new benzamide-containing nitrobenzoxadiazole as a GSTP1-1 inhibitor endowed with high stability to metabolic hydrolysis

  2019cites this paper
• Effects of Glutathione Transferase-Targeting Nitrobenzoxadiazole Compounds in Relation to PD-L1 Status in Human Melanoma Cells

  2019cites this paper
• The activating transcription factor 2: an influencer of cancer progression

  2019cites this paper
• Targeting STAT3 restores BRAF inhibitor sensitivity through miR-759-3p in human cutaneous melanoma cells.

  2018cites this paper
• 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio) hexanol: a promising new anticancer compound

  2018cites this paper
• Glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases

  2018cites this paper
• Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor

  2018cites this paper
• Glutathione S-transferase π: a potential role in antitumor therapy

  2018cites this paper
• Spatio-Genetic and Phenotypic Modelling Elucidates Resistance and Re-Sensitisation to Treatment in Heterogeneous Melanoma

  2018cites this paper
• The nitrobenzoxadiazole derivative MC3181 blocks melanoma invasion and metastasis

  2017cites this paper
• Sox2 is not required for melanomagenesis, melanoma growth and melanoma metastasis in vivo

  2017cites this paper
• Thiol-Activated Anticancer Agents: The State of the Art.

  2016cites this paper
• c-Jun N-terminal kinase activation by nitrobenzoxadiazoles leads to late-stage autophagy inhibition

  2016cites this paper
• Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth

  2016cites this paper
• Screening and identification of Caulis Sinomenii bioactive ingredients with dual-target NF-κB inhibition and β2- AR agonizing activities.

  2016cites this paper
• Malignes Melanom

  2016cites this paper